Role of Otoacoustic Emission in Early Detection of Cisplatin Induced Ototoxicity
© Association of Otolaryngologists of India 2020..
Cisplatin is a chemotherapeutic agent effective against head and neck carcinoma but unfortunately it is cochleotoxic. This study has been designed to investigate the efficacy of OAE in identifying early effects of cisplatin on the cochlea and the importance of protocol for audiological monitoring of cisplatin induced ototoxicity. This is a prospective observational study conducted from October 2012 to September 2014 on 70 patients, receiving Cisplatin for various malignant conditions. Audiological criteria for ototoxicity was considered as a difference of 10 d B or more in pure tone thresholds of two or more adjacent frequencies in conventional audiometry and in DPOAE-Signal noise ratio less than 6 dB or DPOAE amplitude less than 20 dBSPL (irrespective of SNR > 6 dB). According to PTA, 60.7% patients showed ototoxicity after completion of chemotherapy. In DPOAE, according to SNR and amplitude criteria more than 60% patients showed ototoxicity after first cycle of cisplatin at high frequencies (4-8 kHz). DPOAEs is a sensitive tool for early detection of ototoxicity and protocol is necessary for monitoring ototoxicity in patients receiving cisplatin to improve the quality of life.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:74 |
|---|---|
| Enthalten in: |
Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India - 74(2022), Suppl 1 vom: 01. Aug., Seite 164-169 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shetty, Shama [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 02.08.2023 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1007/s12070-020-01933-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM345503589 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM345503589 | ||
| 003 | DE-627 | ||
| 005 | 20231226025213.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12070-020-01933-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1151.xml |
| 035 | |a (DE-627)NLM345503589 | ||
| 035 | |a (NLM)36032922 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shetty, Shama |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Role of Otoacoustic Emission in Early Detection of Cisplatin Induced Ototoxicity |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 02.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © Association of Otolaryngologists of India 2020. | ||
| 520 | |a Cisplatin is a chemotherapeutic agent effective against head and neck carcinoma but unfortunately it is cochleotoxic. This study has been designed to investigate the efficacy of OAE in identifying early effects of cisplatin on the cochlea and the importance of protocol for audiological monitoring of cisplatin induced ototoxicity. This is a prospective observational study conducted from October 2012 to September 2014 on 70 patients, receiving Cisplatin for various malignant conditions. Audiological criteria for ototoxicity was considered as a difference of 10 d B or more in pure tone thresholds of two or more adjacent frequencies in conventional audiometry and in DPOAE-Signal noise ratio less than 6 dB or DPOAE amplitude less than 20 dBSPL (irrespective of SNR > 6 dB). According to PTA, 60.7% patients showed ototoxicity after completion of chemotherapy. In DPOAE, according to SNR and amplitude criteria more than 60% patients showed ototoxicity after first cycle of cisplatin at high frequencies (4-8 kHz). DPOAEs is a sensitive tool for early detection of ototoxicity and protocol is necessary for monitoring ototoxicity in patients receiving cisplatin to improve the quality of life | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cisplatin | |
| 650 | 4 | |a OAE | |
| 650 | 4 | |a Otoacoustic emission | |
| 650 | 4 | |a Ototoxicity | |
| 700 | 1 | |a Bhandary, Satheesh Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Bhat, Vadisha |e verfasserin |4 aut | |
| 700 | 1 | |a Aroor, Rajeshwary |e verfasserin |4 aut | |
| 700 | 1 | |a Shetty, Jayarama |e verfasserin |4 aut | |
| 700 | 1 | |a Dattatreya, T |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India |d 1997 |g 74(2022), Suppl 1 vom: 01. Aug., Seite 164-169 |w (DE-627)NLM093661746 |x 2231-3796 |7 nnns |
| 773 | 1 | 8 | |g volume:74 |g year:2022 |g number:Suppl 1 |g day:01 |g month:08 |g pages:164-169 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12070-020-01933-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 74 |j 2022 |e Suppl 1 |b 01 |c 08 |h 164-169 | ||